Skip to Content
Merck
All Photos(2)

Documents

P8865

SAFC

L-Proline

Synonym(s):

(S)-Pyrrolidine-2-carboxylic acid

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C5H9NO2
CAS Number:
Molecular Weight:
115.13
Beilstein:
80810
EC Number:
MDL number:
UNSPSC Code:
12352209
NACRES:
NA.26

biological source

non-animal source

Assay

≥98.5%

form

crystalline powder

technique(s)

cell culture | mammalian: suitable

impurities

endotoxin, heavy metals, residual solvents, tested

mp

228 °C (dec.) (lit.)

solubility

H2O: 50 mg/mL

application(s)

pharmaceutical (small molecule)

foreign activity

cytotoxicity, tested

SMILES string

OC(=O)[C@@H]1CCCN1

InChI

1S/C5H9NO2/c7-5(8)4-2-1-3-6-4/h4,6H,1-3H2,(H,7,8)/t4-/m0/s1

InChI key

ONIBWKKTOPOVIA-BYPYZUCNSA-N

Looking for similar products? Visit Product Comparison Guide

General description

Our SAFC® portfolio of high-quality raw materials for use in biopharmaceutical processing withstands strict quality control procedures plus the documentation and expertise to help our customers meet requirements as defined by the M-Clarity Program.

M-Clarity Program

Our comprehensive portfolio of upstream process chemicals not only provides biopharmaceutical manufacturers with high-quality raw materials for production of classical and novel therapies, but also helps them get to market faster and simplify regulatory challenges. Trust us to deliver supply chain transparency and reliable sourcing around the globe, streamlining your product qualification with best-in-class regulatory support and service.
To request documentation for this product, please contact Customer Support and select ‘Product Documentation′. Please note that access to the documentation for this product requires a confidentiality disclosure agreement.

Application

L-Proline is a non-essential amino acid. Peptides bond to Proline, making it a useful building block for proteins. It can be used as a cell culture media component for the commercial biomanufacture of therapeutic recombinant proteins and monoclonal antibodies.

Legal Information

SAFC is a registered trademark of Merck KGaA, Darmstadt, Germany

Storage Class Code

11 - Combustible Solids

WGK

WGK 1

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Slide 1 of 1

1 of 1

Marie Couturier et al.
The Journal of biological chemistry, 288(20), 14624-14635 (2013-04-06)
The microbial deconstruction of the plant cell wall is a key biological process that is of increasing importance with the development of a sustainable biofuel industry. The glycoside hydrolase families GH5 (PaMan5A) and GH26 (PaMan26A) endo-β-1,4-mannanases from the coprophilic ascomycete
Michael P Manns et al.
Gastroenterology, 147(2), 366-376 (2014-04-15)
MK-5172 is an inhibitor of the hepatitis C virus (HCV) nonstructural protein 3/4A protease; MK-5172 is taken once daily and has a higher potency and barrier to resistance than licensed protease inhibitors. We investigated the efficacy and tolerability of MK-5172
R A Wevers et al.
Clinical chemistry, 40(7 Pt 1), 1245-1250 (1994-07-01)
Although spin-echo techniques are often used to obtain 1H-NMR spectra of serum or plasma samples, they do not provide reliable quantitative analyses of metabolites. We present a standardized procedure, optimized for sensitivity, for using single-pulse 1H-NMR spectroscopy to analyze deproteinized
David Saadoun et al.
Annals of the rheumatic diseases, 73(5), 831-837 (2013-04-23)
The standard-of-care treatment of patients with hepatitis C virus (HCV)-mixed cryoglobulinemia (MC) vasculitis includes pegylated interferon α (PegIFN)-α plus ribavirin and/or rituximab. About 30-40% of patients are non-responders or relapsers to such combination. To analyse the safety and efficacy of
Salvatore Petta et al.
Hepatology (Baltimore, Md.), 59(5), 1692-1705 (2014-04-03)
We assessed the cost-effectiveness of sofosbuvir (SOF)-based triple therapy (TT) compared with boceprevir (BOC)- and telaprevir (TVR)-based TT in untreated genotype 1 (G1) chronic hepatitis C (CHC) patients discriminated according to IL28B genotype, severity of liver fibrosis, and G1 subtype.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service